A Look At DexCom (DXCM) Valuation After Strong Q1 Growth And Upgraded Profitability Guidance

Simply Wall St.

11小時前

AdvertisementWhy DexCom's latest earnings matter for investors DexCom (DXCM) just reported first quarter 2026 results, with revenue of US$1.192b and net income of US$199.5m, alongside higher margins ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2634424216"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634424216\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634424216?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-05-11 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634424216","market":"hk","top_or_hot":-1,"title":"A Look At DexCom (DXCM) Valuation After Strong Q1 Growth And Upgraded Profitability Guidance","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy DexCom's latest earnings matter for investors DexCom (DXCM) just reported first quarter 2026 results, with revenue of US$1.192b and net income of US$199.5m, alongside higher margins ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/a-look-at-dexcom-dxcm-valuation-after-strong-q1-growth-and-u\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At DexCom (DXCM) Valuation After Strong Q1 Growth And Upgraded Profitability Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At DexCom (DXCM) Valuation After Strong Q1 Growth And Upgraded Profitability Guidance\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-05-11 05:33</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>AdvertisementWhy DexCom's latest earnings matter for investors DexCom (DXCM) just reported first quarter 2026 results, with revenue of US$1.192b and net income of US$199.5m, alongside higher margins ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/a-look-at-dexcom-dxcm-valuation-after-strong-q1-growth-and-u\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/a-look-at-dexcom-dxcm-valuation-after-strong-q1-growth-and-u\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DXCM","symbol_name":"德康醫療","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/a-look-at-dexcom-dxcm-valuation-after-strong-q1-growth-and-u","article_id":"2634424216","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom/news/a-look-at-dexcom-dxcm-valuation-after-strong-q1-growth-and-u","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2634424216","pubTimestamp":1778448816,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why DexCom's latest earnings matter for investors\nDexCom (DXCM) just reported first quarter 2026 results, with revenue of US$1.192b and net income of US$199.5m, alongside higher margins and updated profitability guidance that put cash generation and product momentum in focus.\nSee our latest analysis for DexCom.\nDespite the strong first quarter update and profitability guidance, DexCom's recent share price performance has been weak. The 90 day share price return shows a 12.95% decline and the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"DXCM":"德康医疗"},"translate_title":"第一季度强劲增长和盈利指引升级后DexCom(DXCM)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXCM":1.5},"content_text":"AdvertisementWhy DexCom's latest earnings matter for investors DexCom (DXCM) just reported first quarter 2026 results, with revenue of US$1.192b and net income of US$199.5m, alongside higher margins and updated profitability guidance that put cash generation and product momentum in focus. See our latest analysis for DexCom. Despite the strong first quarter update and profitability guidance, DexCom's recent share price performance has been weak. The 90 day share price return shows a 12.95% decline and the 1 year total shareholder return reflects a 28.63% loss, pointing to fading momentum even as earnings and cash generation remain in focus. If DexCom's earnings story has you rethinking where growth in healthcare technology could come from next, it may be worth scanning for other specialised healthcare AI opportunities via the 35 healthcare AI stocks. With revenue at US$1.192b, rising profits and upgraded margin guidance set against a 1 year total return loss of 28.63%, are you looking at an undervalued CGM leader or a stock where markets already price in future growth? Most Popular Narrative: 27.1% Undervalued With DexCom last closing at $60.91 and the most followed narrative pointing to a fair value of $83.54, the current pricing gap has caught a lot of attention.  The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion.  Read the complete narrative. Curious what kind of revenue build, margin profile, and valuation multiple are baked into that fair value gap? The full narrative spells out a detailed earnings path, share count assumptions, and the required P/E that ties it all together. Result: Fair Value of $83.54 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you still need to weigh the risk that tighter Medicare pricing or stronger CGM competitors could pressure DexCom's margins and slow its growth ambitions. Find out about the key risks to this DexCom narrative. Another View: What The P/E Is Telling You Analysts see DexCom as about 27% undervalued with a fair value of $83.54. The current P/E of 25.3x is higher than both the US Medical Equipment industry at 24.1x and peers at 21.3x, while still below a fair ratio of 29.5x. This combination points to both upside potential and valuation risk if sentiment shifts. To see how this valuation gap could close in practice, including the assumptions behind that higher fair ratio, take a closer look at our detailed multiple breakdown via the See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:DXCM P/E Ratio as at May 2026Next Steps With sentiment clearly focused on whether DexCom's valuation gap is justified, it makes sense to move quickly, review the underlying drivers for yourself, and then see how they line up with the 4 key rewards Looking for more investment ideas? If DexCom has sharpened your focus on where to put fresh capital next, do not stop at one stock. Broaden your watchlist with targeted ideas now.  Target potential mispricings by scanning 51 high quality undervalued stocks that combine quality fundamentals with room for a stronger market view. Strengthen your income stream by reviewing 12 dividend fortresses that pair 5%+ yields with an emphasis on resilience. Reduce portfolio stress by focusing on 71 resilient stocks with low risk scores built around balance sheet strength and lower risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}